454, Solexa Mark Milestones; John West Unmoved by ABI s New Sequencing Plan | GenomeWeb

HILTON HEAD, SC — With the leading next-generation sequencing companies making strides in their pursuit of the $100,000 genome, 454 Life Sciences and rival Solexa have made what they claim are important milestones.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.